Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06315491 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06315491 · ClinicalTrials.gov record · last posted 2026-08-20

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

StatusTerminated
PhasePhase 2
Started2024-09-25
View on ClinicalTrials.gov ↗
Why the trial stopped
Limited clinical activity
from the ClinicalTrials.gov record
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.

Protocol amendment history 3 changes detected by DataLookout

2026-08-21
Trial terminated
2026-08-21
Trial terminated: Limited clinical activity
2026-08-21
Trial sites reduced: 17 → 1 locations
Trial Details
NCT Number NCT06315491
Lead Sponsor Cybrexa Therapeutics
Conditions Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Enrollment 40 participants
Start Date 2024-09-25
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-20